Page last updated: 2024-10-30

metformin and Ureteral Neoplasms

metformin has been researched along with Ureteral Neoplasms in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Ureteral Neoplasms: Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rieken, M1
Xylinas, E1
Kluth, L1
Trinh, QD1
Lee, RK1
Fajkovic, H1
Novara, G1
Margulis, V1
Lotan, Y1
Martinez-Salamanca, JI1
Matsumoto, K1
Seitz, C1
Remzi, M1
Karakiewicz, PI1
Scherr, DS1
Briganti, A1
Kautzky-Willer, A1
Bachmann, A1
Shariat, SF1

Other Studies

1 other study available for metformin and Ureteral Neoplasms

ArticleYear
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem

2014